Neoprobe changes name to Navidea
This article was originally published in Clinica
Executive Summary
Dublin, Ohio-based radiotracer developer Neoprobe has changed its name to Navidea Biopharmaceuticals – a play on the words "navigating ideas". The company said it represents it dedication to "translate cutting edge innovation and precision diagnostics technology into novel products to advance patient care". Also this month, former president and CEO David Bupp retired from his role as director. The moves appear to be part of the firm's strategy of focusing on its lead products, the radiopharmaceutical agents Lymphoseek and RIGScan, which started in May when it sold off its line of gamma detection devices to Devicor Medical Products (www.clinica.co.uk, 26 May 2011).
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.